Sanofi-A Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Jochen Huber

Eugen Uhlmann

Wolfgang Linz

Markus Bleich

Sandra Neumann

Niki Gunkel

Paulus Wohlfart

Evi Kostenis

Aimo Kannt

Stefan Schäfer

Antje Pommereau

Harald Thuering

Martin Oppermann

Kai Rosport

Andreas Bueltmann

Christine Baumgartner

Götz Muench

Martin Ungerer

The present invention relates to oligonucleotide derivatives which are at least partly double-stranded and which have a 2'5&#x2032;-linked oligonucleotide residue on at least one 3&#x2032; end and to the use thereof for specific inhibition of gene expression.

Synthetic double-stranded oligonucleotides for specific inhibition of gene expression

The present invention relates to oligoribonucleotide derivatives which have a 2'5&#x2032;-linked oligoribonucleotide residue without a 5&#x2032;-phosphate residue on the 3&#x2032; end and to the use thereof for specific inhibition of gene expression.

Oligoribonucleotide derivatives for specific inhibition of gene expression

The invention discloses and claims the use of vasopeptidase inhibitors of formula (II) for the treatment of nephropathy in non-diabetic patients.

Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases

The present invention relates to an assay for determining the activity of a G-Protein-Coupled Receptor specific protein kinase by means of an amplified luminescent proximity homo homogenous assay.

High-throughput-assay with high sensitivity for measuring of the activity of &#x3b2;-adrenergic receptor kinase and for determining the impact of test substances on such activity

Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.

Use of EDG2 receptor in an animal model of heart failure

The invention describes and claims the use of vasopeptidase inhibitors of formula (I)for the treatment of nephropathy in diabetic or non-diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistance or of metabolic diseases associated with advanced glycation end-products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and/or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.

Growing community of inventors

Maxdorf, Germany

Jochen Huber